The T1DWATCH Study: a Screening for Type 1 Diabetes Autoantibodies in Children for Early Detection and Intervention.

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-10
SponsorFabiana Sherine Ganem dos Santos

About this trial

This study aims to identify early-stage type 1 diabetes (T1D) in children aged 2-6 and 8-10 years through autoantibody (Ab) screening, genetic and immunological analyses, and to evaluate the effectiveness of educational interventions, as well as the feasibility and acceptability of their implementation.

It is a prospective cohort study involving 2,169 children attending primary healthcare centres in the Barcelonès area. Eligible participants will be those engaged in routine paediatric preventive programe with parental informed consent. The screening process consists of three visits: Visit 1: Capillary blood collection for 3 T1D related Ab (3-screen ELISA). Visit 2: Confirmation of positive results through a new venous blood sample to determine single T1D related Ab and metabolic tests (fasting glucose, HbA1c, C-peptide), HLA, imme cell study. Visit 3: Risk stratification based on Ab presence: Group A (negative), Group B (one positive Ab, at risk of T1D), and Group C (two positive Ab, diagnosed at stage 1 or 2). Immunological and metabolic changes will be monitored, and screening effectiveness will be assessed in terms of sensitivity, specificity, and false positive/negative rates. The association between HLA genotype and Ab positivity will be analysed using logistic regression. A cost-effectiveness analysis will be conducted alongside a qualitative evaluation of parents' and stakeholders' perceptions regarding the screening process.This study will provide evidence to optimise early T1D detection and its implementation in primary care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Young children: 2-6 years

Older children: 7-10 years

Attendance at routine pediatric visits within the Preventive Activities and Health Promotion Programme in Childhood in Catalonia ("Creixer amb Salut") at the specified ages (2-10 years)

Written informed consent provided by parents or legal guardians

Disqualifiers

Presence of primary immunodeficiency

Current treatment with immunosuppressive therapy

Ongoing participation in another clinical trial

Refusal to participate or inability to comply with study procedures

Trial population

The study population consists of children (boys and girls) aged 2-10 years from the three municipalities of Barcelona, spain.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

2,200 Participants
are grouped into 3 trial groups
Group A: Grup A
Group B: Grup B - at risk T1D
Group C: Grup C - Stage 1, 2 T1D

Trial outcomes

Primary outcomes

1

Number of detected cases

Key outcomes include the number of detected cases, defined by the presence of at least one autoantibody or two confirmed Ab.

Time frame
Baseline through study completion, an average of 2 years

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fabiana Sherine Ganem dos Santos

Lead sponsor

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Sponsor institution

Germans Trias i Pujol Research Institute | IGTP

Collaborator

Institut de Recerca Germans Trias i Pujol

Collaborator

This trial is not recruiting at the moment. You can still explore other options: